- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
A minimally invasive procedure called a cardiac catheterization uses a catheter to get access to the heart's blood-filled chambers and coronary circulation. It is done for both interventional and diagnostic purposes.
One of the many diagnostic procedures and tests used in cardiology is coronary catheterization.
Angiocardiography specifically enables the identification of occlusion, stenosis, restenosis, thrombosis, or aneurysmal enlargement of the coronary artery lumens, heart chamber size, heart muscle contraction performance, and some aspects of heart valve function through the injection of a liquid radiocontrast agent and illumination with X-rays.
For up to 2-3% of patients, cardiac catheterization frequently required multiple hours and resulted in serious consequences.
Simple coronary catheterization tests are now routinely performed more quickly and with noticeably better results because of numerous incremental advancements throughout time.
The Global Coronary Catheters market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The iCross Coronary Imaging Catheter, a product or tool created to enhance the deliverability of the company's market-leading intravascular ultrasound technology, the iLab Ultrasound Imaging System, was introduced today by Boston Scientific Corporation.
Doctors may view precise images of the heart and coronary arteries inside the body thanks to IVUS technology. The iCross Catheter will be readily available in the United States, according to the company.
The iCross Coronary Imaging Catheter from Boston Scientific is an effective tool for identifying coronary intravascular pathology, particularly in individuals with complicated coronary artery disease.
They anticipate that the enhancements iCross provides to doctors and their patients will further bolster our dominance in intravascular ultrasonography. A wide variety of interventional medical specialties employ products developed, produced, and marketed by Boston Scientific on a global scale.
The XO Cross Support Catheter Platform from Transit Scientific has received FDA approval for coronary usage. The platform is intended to facilitate wire exchanges, provide a conduit for the supply of saline solutions or diagnostic contrast agents, and guide and support a guidewire during access of the peripheral or coronary arteries.
The XO Cross Support Catheter platform is made to offer new degrees of pushability, trackability, flexibility, and torque responsiveness for access in tortuosity and difficult lesions. High fatigue resistance against challenging complicated lesions present in advanced coronary artery disease (CAD), peripheral artery disease (PAD), and critical limb ischemia is provided by the non-tapered metal-alloy and polymer construction (CLI).
The Prevail drug coated balloon (DCB) Catheter has been introduced in Europe under the CE (Conformité Européenne) label, according to an announcement from Medtronic plc, the world leader in medical technology.
The Prevail DCB, which is the most recent coronary DCB on the market, is used during percutaneous coronary intervention (PCI) operations to treat blocked or restricted coronary arteries in people with coronary artery disease (CAD). The Prevail DCB treats de novo lesions, small vascular disease, and in-stent restenosis using paclitaxel, a medication with fast absorption (ISR).
CARDIAC CATHETERS |
Biosense Webster, a Johnson & Johnson MedTech business, has introduced the Octaray, an eight-spline mapping catheter.A new cardiac mapping device developed by Biosense Webster could help electrophysiologists map cardiac arrhythmias more accurately and effectively.
Biosense, a division of Johnson & Johnson MedTech, has introduced the Octaray Mapping Catheter with Trueref technology driven by the Carto 3 Version 7 System. The novel cardiac mapping catheter was designed for the mapping of cardiac arrhythmias such as atrial fibrillation (AFib).
According to the business, the catheter contains eight splines with enhanced electrode spacing possibilities for quicker and more efficient mapping periods than the Pentaray Nav Eco Mapping Catheter, which may shorten overall ablation operation time frames.
According to the business, the catheter contains eight splines with enhanced electrode spacing possibilities for quicker and more efficient mapping periods than the Pentaray Nav Eco Mapping Catheter, which may shorten overall ablation operation timeframes.
The Octaray is designed to map arrhythmias in any chamber and to provide physicians with greater clarity, speed, and integration to collect exact information for catheter ablation operations.
The device has been approved by the FDA and is CE marked.The Octaray Mapping Catheter's greater surface area coverage and higher signal quality with more splines and electrodes helps me to better understand the anatomy and conduction qualities of the chamber of interest.
"Not only does this catheter help me map more accurately and efficiently, but it also allows for more patient-specific therapy." Trueref technology is a mapping reference electrode that is intended to lessen the effect of farfield signals.
The catheter features 48 tiny mapping electrodes on eight splines, a smaller electrode size, and close electrode spacing. In comparison to the Pentaray Nav Eco, the new cardiac mapping catheter is meant to reliably identify lesion set gaps and improve characterisation of lesion sets. According to Biosense, the Octaray catheter enables for more precise and detailed mapping while improving signal quality.
THIS CORONARY CATHETERS MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS
| Market Segmentation |
| Scope of the report |
| Abbreviations |
| Research Methodology |
| Executive Summary |
| Introduction |
| Insights from Industry stakeholders |
| Cost breakdown of Product by sub-components and average profit margin |
| Disruptive innovation in the Industry |
| Technology trends in the Industry |
| Consumer trends in the industry |
| Recent Production Milestones |
| Component Manufacturing in US, EU and China |
| COVID-19 impact on overall market |
| COVID-19 impact on Production of components |
| COVID-19 impact on Point of sale |
| Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| Product installation rate by OEM, 2023 |
| Incline/Decline in Average B-2-B selling price in past 5 years |
| Competition from substitute products |
| Gross margin and average profitability of suppliers |
| New product development in past 12 months |
| M&A in past 12 months |
| Growth strategy of leading players |
| Market share of vendors, 2023 |
| Company Profiles |
| Unmet needs and opportunity for new suppliers |
| Conclusion |
| Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.